| Name | EGFR-IN-8 |
| Description | EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC. |
| In vitro | In A549, PC9, H1975, CL68, and CL97 cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97 cells at different time intervals, with IC50 values ranging from 0.3 to 0.6 μM and 0.2-0.5 μM after 48 and 72 h of treatment respectively[1]. |
| In vivo | EGFR-IN-8 (50,150 mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : < 1 mg/mL (insoluble or slightly soluble), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | HGFR | HER1 | ErbB-1 | Epidermal growth factor receptor | EGFR-IN-8 | EGFRIN8 | EGFR IN 8 | EGFR | c-Met/HGFR | cMet/HGFR | c-Met | cMet |
| Inhibitors Related | Osimertinib | Decanoic Acid | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Chalcone | Brigatinib | Genistein | Gefitinib | Bacitracin Zinc |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library | Anti-Cancer Compound Library |
United States
